http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0002963-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2000-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed727abe3ebdc4eb8f6d043d012c7f42 |
| publicationDate | 2001-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0002963-A2 |
| titleOfInvention | Use of pyrazolo [4,3-d] pyrimidinone derivatives for the manufacture of a medicament for the treatment of eye diseases |
| abstract | The present invention provides a type 5 cyclic quanosine 3 ', 5'-monophosphate phosphodiesterase inhibitor of formula (I) wherein R 1 is hydrogen, alkyl, cycloalkyl or perfluoroalkyl; R2 is hydrogen, alkyl optionally substituted by hydroxy, alkoxy or cycloalkyl, or perfluoroalkyl; R3 is alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl or cycloalkyl substituted alkyl; R4 is taken together with the nitrogen atom to which the pyrrolidinyl, piperidine, morpholine or 4-N- (R6) substituted piperazinyl group is attached; R5 is hydrogen, alkyl, alkoxy, NR7R8 or CONR7R8; includes the manufacture of a composition for the prevention and treatment of eye diseases and disorders. Transient diseases and conditions include, for example, central retinal artery obstruction; centriretinal artery occlusion, optic nerve disease (including, in particular, ischemic optic nerve disease and glaucoma of the cataract and dry degeneration of the pigment). R2 is hydrogen, alkyl optionally substituted by hydroxy, alkoxy or cycloalkyl, or perfluoroalkyl; R3 is alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl or cycloalkyl substituted alkyl; piperidine, morpholine or 4-N- (R6) substituted piperazinyl; R5 is hydrogen, alkyl, alkoxy, NR7R8, or CON R7R8; |
| priorityDate | 1999-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.